How Fluorescent Tags Modify Oligomer Size Distributions of the Alzheimer Peptide.


Journal

Biophysical journal
ISSN: 1542-0086
Titre abrégé: Biophys J
Pays: United States
ID NLM: 0370626

Informations de publication

Date de publication:
22 01 2019
Historique:
received: 18 07 2018
revised: 14 11 2018
accepted: 03 12 2018
pubmed: 15 1 2019
medline: 3 1 2020
entrez: 15 1 2019
Statut: ppublish

Résumé

Within the complex aggregation process of amyloidogenic peptides into fibrils, early stages of aggregation play a central role and reveal fundamental properties of the underlying mechanism of aggregation. In particular, low-molecular-weight aggregates of the Alzheimer amyloid-β peptide (Aβ) have attracted increasing interest because of their role in cytotoxicity and neuronal apoptosis, typical of aggregation-related diseases. One of the main techniques used to characterize oligomeric stages is fluorescence spectroscopy. To this end, Aβ peptide chains are functionalized with fluorescent tags, often covalently bound to the disordered N-terminus region of the peptide, with the assumption that functionalization and presence of the fluorophore will not modify the process of self-assembly nor the final fibrillar structure. In this investigation, we systematically study the effects of four of the most commonly used fluorophores on the aggregation of Aβ (1-40). Time-resolved and single-molecule fluorescence spectroscopy have been chosen to monitor the oligomer populations at different fibrillation times, and transmission electron microscopy, atomic force microscopy and x-ray diffraction to investigate the structure of mature fibrils. Although the structures of the fibrils were only slightly affected by the fluorescent tags, the sizes of the detected oligomeric species varied significantly depending on the chosen fluorophore. In particular, we relate the presence of high-molecular-weight oligomers of Aβ (1-40) (as found for the fluorophores HiLyte 647 and Atto 655) to net-attractive, hydrophobic fluorophore-peptide interactions, which are weak in the case of HiLyte 488 and Atto 488. The latter leads for Aβ (1-40) to low-molecular-weight oligomers only, which is in contrast to Aβ (1-42). The disease-relevant peptide Aβ (1-42) displays high-molecular-weight oligomers even in the absence of significant attractive fluorophore-peptide interactions. Hence, our findings reveal the potentially high impact of the properties of fluorophores on transient aggregates, which needs to be included in the interpretation of experimental data of oligomers of fluorescently labeled peptides.

Identifiants

pubmed: 30638607
pii: S0006-3495(18)34505-3
doi: 10.1016/j.bpj.2018.12.010
pmc: PMC6350010
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Fluorescent Dyes 0
Peptide Fragments 0
Protein Aggregates 0
amyloid beta-protein (1-40) 0
amyloid beta-protein (1-42) 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

227-238

Informations de copyright

Copyright © 2018 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Références

Biophys J. 2009 Aug 5;97(3):912-21
pubmed: 19651050
Mol Cell Biochem. 1994 Nov 23;140(2):119-25
pubmed: 7898484
R Soc Open Sci. 2017 Jan 4;4(1):160696
pubmed: 28280572
Prion. 2009 Apr-Jun;3(2):89-93
pubmed: 19597329
J Biol Chem. 2012 Aug 31;287(36):30585-94
pubmed: 22767606
Biochem Biophys Res Commun. 2011 Jul 29;411(2):312-6
pubmed: 21726530
Biochemistry. 2004 May 25;43(20):6261-9
pubmed: 15147210
Biochim Biophys Acta. 2015 Dec;1854(12):1860-1870
pubmed: 26374940
Bioinformatics. 2018 Nov 1;34(21):3755-3758
pubmed: 29850778
PLoS One. 2011;6(8):e23970
pubmed: 21901146
J Am Chem Soc. 2016 Aug 17;138(32):10365-72
pubmed: 27434647
ACS Chem Neurosci. 2014 Aug 20;5(8):646-57
pubmed: 24949887
Annu Rev Biochem. 1997;66:385-407
pubmed: 9242912
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):330-5
pubmed: 12506200
J Chem Phys. 2008 Jan 28;128(4):045102
pubmed: 18248009
Nature. 1992 Sep 24;359(6393):325-7
pubmed: 1406936
J Mol Biol. 1968 Mar 14;32(2):343-58
pubmed: 5643439
J Biol Chem. 2002 Aug 30;277(35):32046-53
pubmed: 12058030
Phys Chem Chem Phys. 2014 Apr 28;16(16):7461-71
pubmed: 24626742
PLoS One. 2013 Dec 02;8(12):e82139
pubmed: 24312636
Biochemistry. 1999 Aug 10;38(32):10424-31
pubmed: 10441137
Phys Chem Chem Phys. 2015 Dec 14;17(46):31177-87
pubmed: 26542112
Chem Biol. 1999 Jan;6(1):53-62
pubmed: 9889152
J Biol Chem. 1999 Sep 3;274(36):25945-52
pubmed: 10464339
Protein Sci. 1993 Mar;2(3):404-10
pubmed: 8453378
Annu Rev Neurosci. 2003;26:267-98
pubmed: 12704221
Biophys J. 2009 Sep 2;97(5):1454-60
pubmed: 19720034
J Mol Biol. 1997 Oct 31;273(3):729-39
pubmed: 9356260
Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9
pubmed: 3159021
Biochem Biophys Res Commun. 1984 Aug 16;122(3):1131-5
pubmed: 6236805
J Biol Chem. 2001 Sep 14;276(37):35176-84
pubmed: 11441003
Proc Soc Exp Biol Med. 1969 Sep;131(4):1373-5
pubmed: 5812002
J Am Chem Soc. 2017 Feb 15;139(6):2136-2139
pubmed: 28170248
Biophys J. 2013 Feb 19;104(4):894-903
pubmed: 23442968
Nature. 2003 Dec 18;426(6968):884-90
pubmed: 14685248
Anal Chem. 2015 Dec 1;87(23):11700-5
pubmed: 26489794
Biochemistry. 2010 Apr 13;49(14):3031-9
pubmed: 20201586
Biochemistry. 1993 May 11;32(18):4693-7
pubmed: 8490014
Am J Pathol. 1999 Sep;155(3):853-62
pubmed: 10487842
Nat Struct Mol Biol. 2011 Dec 18;19(1):79-83
pubmed: 22179788
Rev Physiol Biochem Pharmacol. 2007;159:1-77
pubmed: 17846922
J Mol Recognit. 2009 Sep-Oct;22(5):403-13
pubmed: 19343729
Mol Biosyst. 2014 Jan;10(1):34-44
pubmed: 24170094
J Histochem Cytochem. 1968 Nov;16(11):673-7
pubmed: 5723775
Nat Rev Mol Cell Biol. 2014 Jun;15(6):384-96
pubmed: 24854788
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14424-9
pubmed: 18796612
Annu Rev Biochem. 2006;75:333-66
pubmed: 16756495
Ann Neurol. 1999 Dec;46(6):860-6
pubmed: 10589538
FEBS Lett. 2016 Apr;590(7):1028-37
pubmed: 26991731
Anal Biochem. 2008 Nov 1;382(1):29-34
pubmed: 18694719
Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10573-7
pubmed: 7504270
Proteins. 2011;79 Suppl 10:161-71
pubmed: 21987485
Chem Biol. 2014 Jun 19;21(6):732-42
pubmed: 24856820
Micron. 2009 Apr;40(3):285-301
pubmed: 19019688
J Neurosci. 2009 Oct 14;29(41):12787-94
pubmed: 19828790

Auteurs

Jana Wägele (J)

Department of Biotechnology and Biochemistry, Martin-Luther-University Halle-Wittenberg, Halle, Germany.

Silvia De Sio (S)

Department of Biotechnology and Biochemistry, Martin-Luther-University Halle-Wittenberg, Halle, Germany.

Bruno Voigt (B)

Department of Physics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.

Jochen Balbach (J)

Department of Physics, Martin-Luther-University Halle-Wittenberg, Halle, Germany.

Maria Ott (M)

Department of Biotechnology and Biochemistry, Martin-Luther-University Halle-Wittenberg, Halle, Germany. Electronic address: maria.ott@bct.uni-halle.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH